Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GNTA

Genenta Science (GNTA)

Genenta Science SPA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GNTA
DateTimeSourceHeadlineSymbolCompany
2:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Secures Intellectual Property Rights for Listerine "Mouthwash" Antiseptic
1:39PMiHub NewswireFeaturedGolden Heaven Group Holdings Ltd. Announces $6,000,000 Share Repurchase Program
02/12/20244:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNTAGenenta Science SPA
02/08/20245:00AMGlobeNewswire Inc.Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsNASDAQ:GNTAGenenta Science SPA
10/20/20234:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GNTAGenenta Science SPA
09/06/20237:00AMGlobeNewswire Inc.Genenta to Present at Upcoming Scientific and Investor ConferencesNASDAQ:GNTAGenenta Science SPA
07/28/20233:00AMGlobeNewswire Inc.Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsNASDAQ:GNTAGenenta Science SPA
06/29/20237:00AMGlobeNewswire Inc.The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaNASDAQ:GNTAGenenta Science SPA
05/25/20236:04AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GNTAGenenta Science SPA
05/16/20237:00AMGlobeNewswire Inc.Genenta to Provide Update on Lead Product Temferon™NASDAQ:GNTAGenenta Science SPA
05/12/20235:13PMEdgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:GNTAGenenta Science SPA
05/01/20234:06PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
04/26/20237:00AMGlobeNewswire Inc.Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingNASDAQ:GNTAGenenta Science SPA
04/21/20235:23PMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GNTAGenenta Science SPA
03/10/20234:49PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
02/10/20236:10AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GNTAGenenta Science SPA
02/01/20235:29PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
12/22/20224:12PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
10/26/20226:45PMTipRanksMaxim Group Remains a Buy on Genenta Science SpA Sponsored ADR (GNTA)NASDAQ:GNTAGenenta Science SPA
10/25/20225:14PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
10/03/20227:17AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
07/25/20226:00AMGlobeNewswire Inc.AmCham Italy and Genenta Science Announce the Bowling Green Bull InitiativeNASDAQ:GNTAGenenta Science SPA
06/14/20225:12PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GNTAGenenta Science SPA
06/15/200910:47AMPR Newswire (US)The following is an investment opinion release issued by EmergingStockReport.comNASDAQ:GNTA
05/15/200910:48AMPR Newswire (US)Stock Alerts on Market Movers: NGRN, RMBS, NVLS, LVS, GNTA, AN; Issued by Beacon EquityNASDAQ:GNTA
03/06/20097:36PMDow Jones NewsGenta: FDA Favors Clinical Trial For Leukemia Drug GenasenseNASDAQ:GNTAGenta Inc.
03/06/20096:34PMBusiness WireFDA Appeal Decision Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory ...NASDAQ:GNTAGenenta Science SPA
02/13/20094:10PMBusiness WireGenta Incorporated Announces Fourth Quarter and Year End 2008 Financial Results and Corporate HighlightsNASDAQ:GNTAGenenta Science SPA
01/07/20091:02PMPR Newswire (US)Beacon Equity Issues Technical Trade Alerts on Newsworthy Market Movers: WLT, SSCC, FNSR, CHTR, STSI, GNTANASDAQ:GNTA
09/15/20088:05AMPR Newswire (US)Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced MelanomaNASDAQ:GNTA
 Showing the most relevant articles for your search:NASDAQ:GNTA